Want to see AYTU full AI Analyst Report?
Top Page
Aytu BioScience
(NASDAQ:AYTU)
Select Model
Select Model
Rating:54Neutral
Price Target:
$2.00
▼(-13.04% Downside)
Action:Reiterated
Date:09/28/26
Overall score reflects improving financial trajectory (positive operating/free cash flow and reduced leverage) but still-material profitability and revenue volatility risks. Earnings-call commentary is a meaningful positive on EXXUA momentum and a clearer margin/expense framework, while technicals are only moderately supportive and valuation is constrained by negative earnings and no dividend.
Positive Factors
EXXUA adoption momentum
Rapid prescription growth, rising refill activity, and adoption across nearly 1,200 prescribers indicate expanding commercial traction for EXXUA. If this momentum persists, the product could become a larger revenue contributor and improve operating leverage as the sales organization matures.
Negative Factors
Persistent unprofitability
Despite recent quarterly improvement, the company remains unprofitable on a full-year basis, limiting internally funded growth and leaving results sensitive to execution. Sustained losses also indicate that current revenue scale and operating expenses have not yet produced a proven earnings model.
Read all positive and negative factors
Positive Factors
Negative Factors
EXXUA adoption momentum
Rapid prescription growth, rising refill activity, and adoption across nearly 1,200 prescribers indicate expanding commercial traction for EXXUA. If this momentum persists, the product could become a larger revenue contributor and improve operating leverage as the sales organization matures.
Read all positive factors
Aytu BioScience Key Performance Indicators (KPIs)
Any
Revenue by Product
Shows how much revenue each product contributes, highlighting best-sellers and potential areas for growth or concern based on product performance.
Shows how much revenue each product contributes, highlighting best-sellers and potential areas for growth or concern based on product performance.
Data provided by:
The Fly
The FlyAytu BioScience (AYTU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.65M
Dividend YieldN/A
Average Volume (3M)42.89K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue Growth-13.27%
EPS Growth27.11%
CountryUS
Employees76
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.16
Shares Outstanding10,868,208
10 Day Avg. Volume20,253
30 Day Avg. Volume42,893
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.75
Price to Sales (P/S)0.46
P/FCF Ratio8.14
Enterprise Value/Market Cap1.61
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit0.91
Enterprise Value/Ebitda-3.93
Forecast
1Y Price Target
$9.67Price Target Upside320.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$67.86M
Aytu BioScience Business Overview & Revenue Model
Company Description
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes s...
Aytu BioScience Earnings Call Summary
Earnings Call Date:Sep 22, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call was strongly optimistic, centered on EXXUA's accelerating prescriptions, broadening prescriber and patient adoption, favorable access and gross-to-net performance, and a return to positive fourth-quarter adjusted EBITDA. The company also highlighted resilient legacy products, improved operating cash generation, and debt reduction. Challenges included the early stage of the EXXUA launch, temporary sales-force coverage reductions, year-over-year declines in ADHD and pediatrics revenue, lower gross margin versus the prior year, and expected first-half fiscal 2027 profitability and cash-flow softness. Highlights significantly outweighed the lowlights.Positive Updates
Fourth-Quarter Revenue Growth
Fiscal 2026 fourth-quarter net revenue was $16.1 million, up 6% from $15.1 million in the prior-year period and up from $12.4 million in the third quarter, with sequential increases across all three portfolios. Fiscal 2026 net revenue was $57.6 million.
Negative Updates
EXXUA Launch Remains Early
Management said EXXUA remained early in the launch, with the formal launch beginning at the start of January, broader field deployment occurring in late February and early March, and only the first full quarter of launch completed. Many prescribers had used EXXUA for only one or two patients.
Read all updates
Q4-2026 Updates
Positive
Negative
Fourth-Quarter Revenue Growth
Fiscal 2026 fourth-quarter net revenue was $16.1 million, up 6% from $15.1 million in the prior-year period and up from $12.4 million in the third quarter, with sequential increases across all three portfolios. Fiscal 2026 net revenue was $57.6 million.
Read all positive updates
Company Guidance
For fiscal 2027, Aytu is not providing revenue guidance, but its current plan calls for approximately $49 million to $54 million of operating expenses on a GAAP basis and approximately $45 million to $49 million of cash-based operating expenses excluding noncash expenses, including up to $6 million in sales and marketing; research and development expense should remain minimal, and interest expense is expected to continue to decline steadily on a full year basis. Consolidated gross margin is expected to be lowest in the first part of fiscal 2027 and to improve as the year progresses, with a current expectation to approach 66% to 67% gross margin in the fourth quarter of fiscal 2027. Aytu expects lower adjusted EBITDA and operating cash flow in the first half of fiscal 2027 than in the second half, expects the 6-month period ending June 30, 2027, to generate positive adjusted EBITDA, and expects cash flow to improve in the second half.Aytu BioScience Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 57.57M | 66.38M | 65.18M | 107.40M | 96.67M |
| Gross Profit | 36.82M | 45.83M | 49.05M | 66.63M | 50.28M |
| EBITDA | -4.38M | -4.67M | 1.41M | -3.27M | -27.96M |
| Net Income | -14.25M | -13.56M | -15.84M | -17.05M | -108.78M |
Balance Sheet | |||||
| Total Assets | 105.01M | 124.18M | 118.86M | 137.84M | 137.62M |
| Cash, Cash Equivalents and Short-Term Investments | 26.31M | 30.95M | 20.01M | 22.98M | 19.36M |
| Total Debt | 18.11M | 22.94M | 16.42M | 30.43M | 18.19M |
| Total Liabilities | 69.73M | 105.21M | 91.14M | 98.48M | 93.31M |
| Stockholders Equity | 35.27M | 18.97M | 27.72M | 39.36M | 44.31M |
Cash Flow | |||||
| Free Cash Flow | 3.25M | -5.17M | -1.72M | -5.13M | -28.82M |
| Operating Cash Flow | 3.28M | -1.94M | -1.39M | -5.13M | -28.82M |
| Investing Cash Flow | -29.00K | -2.56M | -329.00K | -117.00K | -3.25M |
| Financing Cash Flow | -7.90M | 15.44M | -1.26M | 8.87M | 1.53M |
Aytu BioScience Technical Analysis
Negative
2.30
Price Trends
2.14
Negative
2.18
Negative
2.34
Negative
Market Momentum
-0.05
Positive
36.71
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Negative. The current price of 2.3 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 2.14, and below the 200-day MA of 2.34, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.71 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AYTU.
Aytu BioScience Risk Analysis
Aytu BioScience disclosed 59 risk factors in its most recent earnings report. Aytu BioScience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aytu BioScience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.43B | 107.53 | 40.13% | ― | 81.49% | ― | |
56 Neutral | $127.21M | -11.88 | -47.10% | 16.33% | -25.68% | -244.92% | |
55 Neutral | $20.83M | -95.74 | -0.80% | ― | 27.78% | 52.88% | |
54 Neutral | $20.65M | -1.39 | -52.89% | ― | -13.27% | 27.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $5.32M | -0.91 | -53.56% | ― | 47.00% | 50.49% | |
41 Neutral | $3.76M | -3.12 | 206.75% | ― | ― | ― |
* Healthcare Sector Average
AYTU
Aytu BioScience
1.90
-0.31
-14.03%
SNOA
Sonoma Pharmaceuticals
1.11
-2.89
-72.25%
TXMD
TherapeuticsMD
1.80
0.49
37.40%
RDHL
RedHill Biopharma
0.42
-1.15
-73.06%
CPIX
Cumberland Pharmaceuticals
8.49
6.02
243.31%
ETON
Eton Pharmaceuticals
50.00
31.52
170.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.